CDK4 and non-small cell lung carcinoma: PI3K-AKT-mTOR and RASRAF-MEK-ERK pathway inhibitors showed synergistic tumor inhibition in many preclinical vitro and vivo models in NSCLC with CDK4/6 inhibitors (50–52).